20 results about "In vivo tests" patented technology

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The present invention discloses a nanobody, fusion protein and application that specifically binds to FAdV-4, and belongs to the technical field of veterinary biological products. Based on the phage nanobody display library of FAdV-4, the present invention screened specific nanoantibodies against FAdV-4 fiber protein 2 (Fiber 2), and used the self-assembly technology of ferritin to genetically engineer the nanoantibodies to express and prepare the anti-FAdV-4 polymerized nanoantibody Fenobody-75. The antibody is simple to express and purify, has stable properties and low production cost. The antiviral effect was analyzed by in vitro and in vivo tests. The results show that the Fenobody-75 of the present invention is highly safe and has a good protective effect against FAdV-4 infection. Therefore, Fenobody-75 has a good market application prospect as a biological preparation for resisting FAdV-4 infection in poultry.

An in-vivo testing device is disclosed for dynamically measuring the mechanical properties of skin. The device includes a horizontal reciprocating tensile stress-strain detection unit configured to contact the skin surface and acquire displacement and tensile force data, wherein the detection unit comprises at least two contact heads. A driving unit, equipped with a motor capable of outputting reciprocating linear motion perpendicular to the skin surface, is provided to drive the contact heads. A reversing unit converts the perpendicular reciprocating linear motion into a horizontal reciprocating tensile motion of the contact heads relative to the skin surface. The reversing unit includes at least one right-angle reversing lever connecting the driving unit and the detection unit. The disclosed device enables reliable evaluation of the dynamic viscoelastic properties of skin in a non-destructive manner, thereby providing accurate and repeatable characterization of skin biomechanics under in-vivo conditions.

MR image data can be improved by using a complex de-noising convolutional neural network such as a non-blind C-DnCNN, a network for MRI denoising that leverages complex-valued data with phase information and noise level information to improve denoising performance in various settings. The proposed method achieved superior performance on both simulated and in vivo testing data compared to other algorithms. The utilization of complex-valued operations allows the network to better exploit the complex-valued MRI data and preserve the phase information. The MR image data is subject to complex de-noising operations directly and simultaneously on both real and imaginary parts of the image data. Complex and real values are also utilized for block normalization and rectified linear units applied to the noisy image data. A residual image is predicted by the C-DnCNN and a clean MR image is available for extraction.

Provided herein are methods and compositions related to in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., testing the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents in genetically modified rodents). In some embodiments, the genetically modified rodents express antibodies comprising a human Fc (e.g., human IgG1 Fc, human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (γ or κ) chains). In certain embodiments, the genetically modified rodent comprises one or more Fc receptors with human extracellular domains (e.g., neonatal Fc receptor (FcRn), β-2-microglobulin polypeptide (β2M), Fcε receptor 1α (FcεR1α), Fcγ receptor 1α (FcγR1a), Fcγ receptor 2a (FcγR2a), Fcγ receptor 2b (FcγR2b), Fcγ receptor 3a (FcγR3a), Fcγ receptor 3b (FcγR3b), Fcγ receptor 2c (FcγR2c)). The transmembrane and cytoplasmic domains of the receptor can be human or non-human (e.g., rodent).

The invention relates to the technical field of food analysis, and provides a method for analyzing the sensitization effect of natural carbohydrate chains on food allergens, which comprises the following steps: extracting and purifying tropomyosin freeze-dried powder in food muscle tissues, identifying the types of carbohydrate chains in the tropomyosin freeze-dried powder, and analyzing the types of glucosidic bonds; removing an N-carbohydrate chain and an O-carbohydrate chain in the tropomyosin freeze-dried powder by using one or more of a PNGase F enzyme removal method, a beta-elimination method and a trifluoromethanesulfonic acid method, so as to obtain a deglycoprotein; a phenol-sulfuric acid method, SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and PAS (Polyacrylamide Sulfate) dyeing are used for evaluating the anti An in vitro test and an in vivo test are used to evaluate the effect of the desugaring treatment on the allergenicity of tropomyosin. By analyzing the regulation influence of the natural carbohydrate chain on the allergenicity of the penaeus chinensis tropomyosin, a foundation is laid for deep research on the allergenicity of the penaeus chinensis tropomyosin, and an innovative perspective of analyzing the allergenicity characteristics of the penaeus chinensis tropomyosin is provided.

The invention belongs to the field of medical treatment, and discloses an application of 11-MT in medicine preparation. The medicine refers to a medicine for treating acute B lymphocytic leukemia. Researches show that 11-MT shows the following advantages in treatment of acute B lymphocytic leukemia: in an in-vitro test, 11-MT significantly promotes apoptosis of BALL-1 cells and shows dose dependence, 11-MT significantly promotes generation of ROS in the BALL-1 cells and shows dose dependence, 11-MT can cause DNA damage of the BALL-1 cells and shows dose dependence, and in an in-vivo test, 11-MT can significantly promote apoptosis of the BALL-1 cells and shows dose dependence. The 11-MT has a regulating effect on specific organ lesions, shows good repairing and protecting effects, can recover multiple serum biochemical indexes abnormally increased due to tumor load to a normal level, and can well reduce tumor cell infiltration.

The invention discloses an engineered exosome targeting delivery system (EMT-Cas12a) and application thereof in AIDS (acquired immune deficiency syndrome) treatment. The targeting delivery system is loaded with a functional component for cutting HIV (human immunodeficiency virus) previrus DNA (deoxyribonucleic acid) on the basis of CRISPR-Cas12a (clustered regularly interspaced short palindromic repeats). According to the targeting delivery system, a nano antibody Nb1 of targeting CD4 is expressed on the surface of EMT-Cas12a, so that the efficiency of targeting delivery of CRISPR-Cas12a to CD4 + cells is improved. According to the targeted delivery system, a multi-crRNA series strategy is designed, a conserved region shared by a targeted HIV-1 B subtype and Chinese epidemic strains (07BC, 08BC and B ') is conserved, the crRNA and Cas12a mRNA form a functional component for cutting HIV previrus DNA, the functional component and Cas12a mRNA are jointly packaged into EMT-Cas12a, and the risk of virus escape is reduced. According to the targeting delivery system, in cells cultured in vitro (cell lines infected with HIV-1 and PBMC derived from HIV-1 positive donors), and in vivo tests of intravenous injection of EMT-Cas12a in humanized mice infected with HIV-1, good biological safety characteristics and excellent antiviral efficacy are proved.

Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group.

The application belongs to the technical field of biology and relates to a nanobody or antigen-binding fragment thereof specifically binding to pig IgM Fc receptor FcμR and application. The application clones full-length cDNA of pig FcμR, expresses the extracellular region in prokaryotes, and constructs a nanobody library by camel immunization; a strain of specific anti-pig FcμR nanobody is obtained through three rounds of panning. The nanobody (FcμR-VHH) is expressed by E. coli, and it is proved that the nanobody can target pig macrophages (PAMs) by taking zsGreen as a model. In vitro and in vivo tests show that the targeting and immune enhancement effect of the FcμR-VHH fusion protein at the C-terminal of an antigen is better than that at the N-terminal. After immunizing animals, ELISA proves that the fusion protein significantly improves humoral and cellular immune responses.

This document provides methods and compositions relating to mice that express human or humanized Fcα receptors (FcαR) from the FcαR locus located in the mouse leukocyte receptor complex (LRC). In some embodiments, such mice can be used for in vivo testing of therapeutic agents containing human IgA Fc (e.g., testing of the pharmacokinetic and / or pharmacodynamic properties and dosing regimens of such therapeutic agents). This document also provides methods for using such mice, cells derived from such mice, methods for preparing such mice, and ES cells containing the same genetic modifications as such mice.

The invention belongs to the technical field of biology, and discloses application, a screening method and a medicine of Brawler's bacteria, and application of the Brawler's bacteria to preparation of anti-inflammatory drugs. Firstly, it is determined that intestinal microorganisms play an important role in resisting salmonella infection through a fecal microorganism transplantation test; secondly, screening is carried out on excrement extracts of chicken infected with salmonella, it is found that the abundance of the Brawler is extremely high, and it is further found through in-vitro tests and in-vivo tests that the Brawler can inhibit the systemic inflammatory response, caused by infection of salmonella enteritidis, of the chicken.

The application discloses a kind of pharmaceutical compositions, it includes stilben compound and pharmaceutically acceptable adjuvant;Wherein, the stilben compound is Pterostilbene or its pharmaceutically acceptable salt, the pharmaceutically acceptable adjuvant includes glucosyl tangeritin and / or glycyrrhizic acid salt.The in vitro and / or in vivo test results show that the pharmaceutical composition provided by the application has good curative effect for preventing and / or treating drug-induced liver injury;Meanwhile, it can also significantly reduce serum transaminase level, alleviate the symptoms such as liver and spleen edema, and also has good inhibitory effect on proinflammatory cytokines.The test results further show that stilben compound and pharmaceutically acceptable adjuvant (including glucosyl tangeritin and / or glycyrrhizic acid salt) combination, good safety, and easy to dissolve, release and / or absorption etc., improve the bioavailability of Pterostilbene (PTE), have synergistic effect, and have good application prospect.

A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA / RNA / PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.

A system of in vivo testing for the presence of recently viable dental cellular debris, from an endodontic cavity and other areas of a tooth by testing for the presence of cellular debris using indica

Provided herein are methods and compositions related to in vivo testing of therapeutic agents comprising human Fc in genetically modified rodents (e.g., testing pharmacokinetic and / or pharmacokinetic properties of such therapeutic agents in genetically modified rodents). In some embodiments, the genetically modified rodent expresses an antibody comprising a human Fc (e.g., human IgG1 Fc, human IgG4 Fc). In some embodiments, the rodent expresses a fully human antibody (i.e., an antibody having a human heavy chain and a human light (gamma or kappa) chain). In certain embodiments, the genetically modified rodents comprise one or more Fc receptors having a human extracellular domain (e.g., neonatal Fc receptor (FcRn), beta-2-microglobulin polypeptide (beta2M), Fc epsilon receptor 1 alpha (Fc epsilon R1 alpha), Fc gamma receptor 1 alpha (Fc gamma R1a), Fc gamma receptor 2a (Fc gamma R2a), Fc gamma receptor 2b (Fc gamma R2b), Fc gamma receptor 3a (Fc gamma R3a), Fc gamma receptor 3b (Fc gamma R3b), Fc gamma receptor 2c (Fc gamma R2c)). The transmembrane and cytoplasmic domains of the receptors can be human or non-human (e.g., rodents).

The application belongs to the field of medicine, and relates to a butyrylcholinesterase selective inhibitor and a preparation method and application thereof. The application provides a brand-new butyrylcholinesterase selective inhibitor skeleton, in-vitro verification shows that part of the compounds have extremely high butyrylcholinesterase inhibitory activity and selectivity, in-vivo testing finds that a representative compound has an obvious cognitive improvement effect on an AD mouse model, and the butyrylcholinesterase selective inhibitor provided by the application has the potential to be used as a drug for preventing or treating Alzheimer's disease.

Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice.

The invention provides an amide derivative as shown in a formula (I), or a tautomer, a stereoisomer or pharmaceutically acceptable salt thereof, and application of the amide derivative or the tautomer, the stereoisomer or the pharmaceutically acceptable salt. In-vitro experiment results show that the compound disclosed by the invention has relatively strong MAO-B selective inhibition activity. In-vivo test results show that the compound provided by the invention can significantly reduce the body weight of mice under the condition of not influencing the food intake.